Biolife Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>BS</div>
BLFS -- USA Stock  

USD 33.70  0.11  0.33%

In general, we focus on analyzing Biolife (NASDAQ:BLFS) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biolife Solutions daily price indicators and compare them against related drivers. Let's first try to sum up why Biolife Solutions investors are seeking stability amid unprecedented economic uncertainty.
Published over three weeks ago
View all stories for Biolife Solutions | View All Stories
Is Biolife Solutions (NASDAQ:BLFS) losing trust from retail investors?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biolife Solutions has an asset utilization ratio of 336.79 percent. This connotes that the company is making $3.37 for each dollar of assets. An increasing asset utilization means that Biolife Solutions is more efficient with each dollar of assets it utilizes for everyday operations.
About 19.0% of the company shares are held by company insiders. Biolife Solutions has Price/Earnings (P/E) ratio of 311.95. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 29th of January 2014.
The successful prediction of Biolife Solutions stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Biolife Solutions, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Biolife Solutions based on Biolife Solutions hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Biolife Solutions's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Biolife Solutions's related companies.

Use Technical Analysis to project Biolife expected Price

Biolife Solutions technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Biolife Solutions technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Biolife Solutions trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Biolife Solutions, but it might be worth checking our own buy vs. sell analysis

What is driving Biolife Solutions Investor Appetite?

The company reported the previous year's revenue of 41.66 M. Net Income was 7.3 M with profit before overhead, payroll, taxes, and interest of 18.9 M.
 2018 2020 2021 (projected)
Interest Expense5 K4.5 K4.62 K
Gross Profit13.53 M21.4 M23.09 M

Deferred Revenue Breakdown

Biolife Solutions Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Deferred Revenue is likely to grow to about 106.1 K this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Biolife Solutions Deferred Revenue is relatively stable at the moment as compared to the past year. Biolife Solutions reported last year Deferred Revenue of 98,250.3
2010
2011
2012
2020
2021
2010149,167
2011129,167
2012109,167
202098,250.3
2021106,097

Are Biolife Solutions technical ratios showing a relapse?

Biolife Solutions latest skewness advances over 0.21. Biolife Solutions exhibits very low volatility with skewness of 0.21 and kurtosis of -0.13. However, we advise investors to further study Biolife Solutions technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biolife Solutions' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biolife Solutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Takeaway

While some other entities under the medical instruments & supplies industry are still a bit expensive, Biolife Solutions may offer a potential longer-term growth to retail investors. In closing, as of the 21st of March 2021, we believe Biolife Solutions is currently fairly valued. It slowly supersedes the market and projects close to average probability of distress in the next two years. Our concluding 30 days 'Buy-Sell' recommendation on the enterprise is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Biolife Solutions. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com